Grünenthal Initiates Phase II Trial for Innovative Nociceptin Receptor Agonist – The first patient has been enrolled in a Phase II trial for a novel NOP agonist targeting acute pain relief. – The investigational treatment aims to offer a safer alternative for patients post-surgery. – Phase I results indicated excellent safety and tolerability, leading to the progression into Phase II.
No responses yet